| Outcome Measures: |
Primary: TEAE, Incidence of treatment-emergent adverse events (TEAE), after 28/35 days of treatment | Secondary: Cmax, The peak concentration after reaching the target dose, 28/35 days|AUClast, the area under the concentration-time curve from 0 to the last time that the concentration can be accurately measured, 28/35 days|AUC0-inf, the area under the concentration-time curve from 0 to infinity, 28/35 days|Tmax, the peak time, 28/35 days|λz, the elimination rate constant, 28/35 days|t1/2, the half-life, 28/35 days|tlag, retention time, 28/35 days|CL/F, apparent clearance rate, 28/35 days|Vz/F, apparent volume of distribution, 28/35 days|AUC%extra, extrapolation percentage of AUC0-in, 28/35 days|MRT, average retention time, 28/35 days|AUCglucose0-14h, area under the concentration-time curve of fasting blood glucose from 0 to 14 hours after each administration, 28/35 days|AUCc-peptide0-14h, area under the concentration-time curve of fasting C-peptide from 0 to 14 hours after each administration, 28/35 days|AUCinsulin0-14h, area under the concentration-time curve of fasting insulin from 0 to 14 hours after each administration, 28/35 days|body weight, 28/35 days|body mass index (BMI）, 28/35 days
|
